NEWS
edited by Fabio Arcangeli
Hebert A. Hyperhidrosis. Presented at: South Beach Symposium; February 5–7, 2026; Miami Beach, Florida.
Hebert A. Hyperhidrosis. Presented at: South Beach Symposium; February 5-7, 2026; Miami Beach, Florida. Hyperhidrosis, a condition characterized by excessive sweating of the armpits, palms, soles, and face, typically develops in children within...
De Rosas EC, et al. JAMA Dermatology. 2026
De Rosas EC, et al. JAMA Dermatol. 2026 Mycophenolate mofetil has been shown to be equally effective and more tolerable than methotrexate in the treatment of juvenile localized scleroderma. Juvenile localized scleroderma (JLS), also known as morphea, is a...
Kobylinski KC, et al. Oral ivermectin is safe in children weighing 5 to less than 15 kg — a multicenter trial. Presented at: American Society of Tropical Medicine & Hygiene Annual Meeting; Nov. 9-13, 2025; Toronto.
Kobylinski KC, et al. Oral ivermectin is safe in children weighing 5 to less than 15 kg — a multicenter trial. Presented at: American Society of Tropical Medicine & Hygiene Annual Meeting; Nov. 9-13, 2025; Toronto. Children weighing less than 15 kg are...
Koselugo (selumetinib) for the treatment of type 1 neurofibromatosis with symptomatic and inoperable plexiform neurofibromas is now approved in the United States, the European Union, and Asia for adults.
Koselugo (selumetinib) for the treatment of type 1 neurofibromatosis with symptomatic and inoperable plexiform neurofibromas is now approved in the United States, the European Union, and Asia for adults. The approval of Koselugo was based on data from the study...
The FDA has approved remibrutinib (Rhapsido, Novartis), a Bruton's tyrosine kinase inhibitor, as the first oral treatment for adults with persistent chronic spontaneous urticaria (CSU) resistant to H1 antihistamine therapy.
The FDA has approved remibrutinib (Rhapsido, Novartis), a Bruton's tyrosine kinase inhibitor, as the first oral treatment for adults with persistent chronic spontaneous urticaria (CSU) resistant to H1 antihistamine therapy. CSU affects approximately 1.7...
F Xiang, et al. Abstract #LBA-213. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 17-20, 2025; Paris.
F Xiang, et al. Abstract #LBA-213. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 17-20, 2025; Paris. Denifanstat, a fatty acid synthase inhibitor, has been shown to be effective in the treatment of moderate to severe acne vulgaris...
The FDA has approved Zoryve cream (roflumilast) 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis.
The FDA has approved Zoryve cream (roflumilast) 0.05% for the treatment of children aged 2 to 5 years with mild to moderate atopic dermatitis. "Younger children with AD are children with specific medical needs," Dr. Lawrence F. told Healio....
"The Association of Psoriasis and Bacterial Infections in Pediatric Patients: A Retrospective Review."
Ravi M et al. Pediatric dermatology. 2025;42(4):735-741. https://doi.org/10.1111/pde.16007 Guttate psoriasis onset and plaque psoriasis flares are associated with streptococcal pharyngitis. Literature regarding the relationship between anogenital bacterial dermatitis...
"Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials."
Bhatia N et al. JAMA Dermatol. 2025;161(5):499. Low-dose doxycycline is an established treatment for papulopustular features of rosacea that may reduce the adverse effects of doxycycline treatment; however, data on low-dose regimens for other tetracyclines are...
The FDA issued a warning about risk for severe itching after stopping long-term allergy medication use (cetirizine...)
The FDA issued a warning about the risk of severe itching after stopping long-term allergy medication use (cetirizine...) as well as updated prescribing information stating that symptoms may improve when restarting the medicines.